A Prospective, Comparative, Open Label, Randomized, Multicentric, Phase III study to compare the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited against Avastin in Patients with Unresectable or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Latest Information Update: 03 Jul 2019
At a glance
- Drugs Bevacizumab (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Intas Pharmaceuticals
Most Recent Events
- 03 Jul 2019 New trial record